Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: Rationale and clinical relevance

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 4, Issue 3, 2003, Pages 149-154

  Meune, Christophe ^a   Mourad, Jean Jacques ^b   Bergmann, Jean François ^c   Spaulding, Christian ^a  

^a Institut Cochin   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Aspirin; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIFLUSAL; WARFARIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PROSTAGLANDIN SYNTHESIS INHIBITION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; THROMBOCYTE AGGREGATION; WATER RETENTION;

EID: 0242692725     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2003.023     Document Type: Review

References (62)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Mann DL. Mechanisms and models in heart failure. Circulation 1999;100:999-1008.
3. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-70.
4. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia.N Engl J Med 1984;310:347-52.
5. Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 1998;31:1679-86.
6. Schrör K. Role of Prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors.J Cardiovasc Pharmacol 1992;20:S68-S73.
7. Cannon PJ. Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. Am J Med 1986;82:123-32.
8. Cleland JGF, Bulpitt CJ, Falk RH et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-19.
9. Mahé I, Meune C, Diemer M, Caulin C, Bergmann JF. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Safety 2001;24:167-82.
10. Spaulding C, Charbonnier B, Cohen-Solal A et al. Acute heamodynamic interaction of aspirin and ticlodipine with enalapril. Circulation 1998;98:757-65.
11. Schwieler JH, Kahan T, Nussberger J et al. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms.Am J Physiol 1993;264:E631-E637.
12. Wagner C, Kurtz A. Regulation of renal renin release. Curr Opin Nephrol Hypertens 1998;7:437-41.
13. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 1994;87:567-74.
14. Minshall RD, Tan F, Nakamura F et al. potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res 1997;81:848-56.
15. Regoli D, Rhaleb NE, Drapeau G et al. Basic pharmacology of kinins:pharmacologic receptors and other mechanisms. In: Abe K, Moriya H, Fuji S. New York: Plenum, 1989;398-407.
16. Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997; 54(suppl 5):23-30.
17. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.
18. Townend JN, Doran J, Lote CJ, Davies MK. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J 1995;73:734-41.
19. Emanueli C, Maestri R, Domenico C et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999;100:2359-65.
20. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5.
21. Needleman P, Isakson PC. The discovery and function of COX-2.J Rheumatol 1997;24(suppl 49):6-8.
22. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxydase synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal antiinflammatory drugs.J Biol Chem 1993;268:6610-14.
23. Patrignani P, Filabozzi P, Patrono C. Selective inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.J Clin Invest 1982;69:1366-72.
24. Weskler BB, Pett SB, Alonso D et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-05.
25. Baur LHB, Schipperheyn JJ, Van der Laarse A et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
26. Fitzgerald GA, Oates JA, Hawiger OJ et al. Endogenous biosynthesis of prostacycline and thromboxane and platelet function during chronic administration of aspirin in men. J Clin Invest 1983;71:976-88.
27. The SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Daguenais G for The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
29. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor trials. Overview of randomized trials of angiotensin-converting enzyme inhibitor on mortality and morbidity in patients heart failure.JAMA 1995;273:1450-6.
30. Lorel BH. Pericardial disease. In: Braunwald E (ed.). Heart Disease. A textbook of cardiovascular medicine. 5th edition Philadelphia:W.B. Saunders Company, 1997;1478-534.
31. Albert DA, Harel L, Karrisson T. The treatment of rheumatic carditis: A review and meta-analysis. Medicine 1995;74:1-12.
32. Brooks PM, Day RO. Non-steroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991;324: 1716-25.
33. Antiplatelet Trialists Collaboration. Collaborative overview of randomised, controlled trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
34. Hansson L, Zanchettti S, Carruthers SG et al. for the HOT study group. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
35. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22:6A-13A.
36. Brater DC. Effect of indomethacin on salt and water homeostasis. Clin Pharmacol Ther 1979;25:322-30.
37. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Int Med 1993;153:477-84.
38. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary health disease. Part 2, Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
39. Gottlieb SS, Robinson S, Krichten CM, Fisher ML. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70:890-3.
40. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000;160:777-84.
41. Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998;18:1041-52.
42. Bhagat K, Collier J, Vallance P. Vasodilatation to arachidonic acid in humans.An insight into endogenous prostanoids and effects of aspirin. Circulation 1995;92:2113-18.
43. Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharmacol Ther 2000;67:530-7.
44. Galatius S, Wroblewski H, Kastrup J. Does aspirm treatment influence vascular resistance and fluid filtration in patients with congestive heart failure? Heart 1999;81:330.
45. Guazzi MD, Campodonico J, Celeste F et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998;63:79-86.
46. Meune C, Mahe I, Mourad JJ et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.
47. Latini R, Santoro E, Masson S et al. for the GISSI-3 investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction. Results of the GISSI-3 trial. Heart Disease 2000;2:185-90.
48. Zanetti G, Latini R, Maggioni AP, Franzosi MG, Santoro L, Tognoni G, for the GISSI-3 investigators. Effects of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 1997;96:4239-45.
49. Latini R, Tognoni G, Maggioni AP et al. on behalf of the Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence or absence of aspirin. J Am Coll Cardiol 2000;35:1801-07.
50. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000;35:1808-12.
51. Takkouche B, Etminan M, Caamaño, Rochon PA. Interaction between aspirin and ACE inhibitors. Resolving discrepancies using a meta-analysis. Drug Safety 2002;25:373-8.
52. Krumholz HM, Chen Y-T, Wang Y, Radjford MJ. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med 2001;161:538-44.
53. Garcia-Dorado D, Rami JV, Lamela AV et al. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J Supplements 1999;1(suppl F):F24-F28.
54. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA.Antiplatelet agents and survival: a cohort analysis from the Studies Of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.
55. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroups analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-19.
56. Teo KK Yusuf S, Pfeffer M et al. for the ACE inhibitors collaborative group. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43.
57. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilatator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
58. Aumégeat V, De Groote P, Meurice T, Millaire A, Ducloux G, Lablanche JM. Aspirin and angiotensin converting enzyme inhibitors in 445 patients with moderate congestive heart failure. J Am Coll Cardiol 1999;33:214A.
59. Harjai KJ, Nunez E, Turgut T, Newman J. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. Am J Cardiol 2001;87: 483-7.
60. Jones CG, Cleland JGF. The LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Fail 1999;1:425-31.
61. Tenenbaum A, Grossman E, Shemesh J, Fizman EZ, Nosraty I, Motro M. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens 2000;13:776-82.
62. Meune C, Mahé I, Mourad JJ et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail 2003;5:271-9.